A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.
Together with colleagues from Sweden and Luxembourg, scientists from the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have observed that, during a natural vaginal birth, specific bacteria from the mother's gut are passed on to the baby and stimulate the baby's immune responses. This transmission is impacted in children born by caesarean section.
Researchers have found that genetic mutations affecting the capsid, the structure surrounding the HIV genome, make it possible for a protein called TRIM5α to trigger the immune system of elite controllers.
Algunos virus son capaces de apoderarse de una enzima que supuestamente previene enfermedades autoinmunitarias con el fin de evitar ser detectados. Este descubrimiento de los investigadores de Mayo Clinic y de sus colaboradores se publica en PLOS Biology.
MSK experts in CAR-T therapy, immunotherapy, leukemia, lymphoma, blood and marrow stem cell transplantation, and more, are also available to comment on meeting news.
ROCHESTER, Minn. — An enzyme intended to prevent autoimmune disease can be hijacked and used by some viruses to avoid immune detection. That discovery from Mayo Clinic researchers and collaborators appears in PLOS Biology. There's also good news. The same team also defined how much viral genetic material is needed to reverse the process and instead activate the immune system against the virus.
In a proof-of-principle study, researchers at Johns Hopkins revealed that certain immune system cells found in the human liver, called liver macrophages, contain only inert HIV and aren’t likely to reproduce infection on their own in HIV-infected people on long-term antiretroviral therapy (ART). ART is a regimen containing combinations of HIV-targeting drugs that prevents the growth of the virus but does not eradicate it.
Scientists have long wondered how one protein, NLRP3, can promote inflammation in response to a wide range of seemingly unrelated stimuli.
The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. The findings were presented at the Society for Neuro-Oncology Annual Meeting in New Orleans.
Latest Cancer Research Institute update on the landscape of anti-PD1/L1 checkpoint inhibitor clinical trials
Researchers at Johns Hopkins have identified two patients with HIV whose immune cells behave differently than others with the virus and actually appear to help control viral load even years after infection. Moreover, both patients carry large amounts of virus in infected cells, but show no viral load in blood tests. While based on small numbers, the data suggest that long-term viral remission might be possible for more people.
In an effort to compile and summarize the latest knowledge about these immunotherapy combinations and their implications, a group of kidney cancer immunotherapy experts led by Saby George, MD, of Roswell Park Comprehensive Cancer Center have written a new research review article assessing current approaches to treating patients newly diagnosed with kidney cancer and also looking ahead to some of the most pressing questions still to be answered related to these emerging therapies. Published online Nov. 21 by the journal JAMA Oncology, the review article highlights the path to approval for the new standard of care for these patients — ipilimumab, also known as Yervoy, together with nivolumab, also known as Opdivo.
New research reveals a need for better tools for catching severe infections in pregnant women and simple early interventions clinicians can take now to save lives.
If you can reduce the overall stress that comes with the holidays, maybe you can also cut down your allergy and asthma symptoms
Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new immunotherapies, will receive $1 million in initial funding from Stand Up to Cancer. The project led by researchers from The University of Texas MD Anderson Cancer Center and Baylor College of Medicine will collect T cells – the immune system’s targeted warriors -- from tumors, expand their number by the billions and then customize them to resist being shut down by a common substance that’s abundantly produced in tumor tissue
About a year after receiving daily oral immunotherapy for severe peanut allergy, 67 percent of children in a Phase 3 trial were able to tolerate eating at least two peanuts (600 mg) without an allergic reaction, while 50 percent tolerated eating three to four peanuts (1,000 mg) without symptoms. At the start of the study, all of these children had allergic reactions after ingesting just 1/10 of a peanut (30 mg). These results of an international, randomized, double-blind, placebo-controlled trial conducted at 66 sites, including Ann & Robert H. Lurie Children’s Hospital of Chicago, were published in the New England Journal of Medicine.
About half of all people with cystic fibrosis, the most common genetic disorder in the United States, die from a lung disease before they turn 40. A form of pneumonia called Pseudomonas aeruginosa is a likely culprit. WVU researcher Mariette Barbier is pursuing new ways to vaccinate at-risk populations against this deadly illness.
Controlled ingestion of peanut protein could help build tolerance in peanut allergy sufferers. Authors of a new study published in the New England Journal of Medicine say an oral immunotherapy drug they tested could be the first FDA-approved medication of its kind for people with peanut allergy. The medication, called AR101, is derived from peanut protein.
New ACAAI President and President-Elect take office
The American Autoimmune and Related Diseases Association is honored to announce the winners of its 2018 Young Investigator Grants
Trying to understand why some breeds of sheep are more susceptible to parasitic infection than others is a puzzle, but researchers in the WVU Davis College of Agriculture, Natural Resources and Design are putting it together piece by piece.
Many parents probably think nothing of sucking on their baby’s pacifier to clean it after it falls to the ground. Turns out, doing so may benefit their child’s health. A Henry Ford Health System study found that babies whose parents sucked on their pacifier to clean it had a lower level of the antibody that is linked to the development of allergies and asthma.
New research suggests a link between parental sucking on a pacifier and a lower allergic response among young children.
New research shows it’s possible for both children and adults with uncontrolled asthma to find their symptoms worsening due to cannabis allergy and exposure to marijuana smoke.
New research found allergy shots provided significant benefits to the eczema symptoms suffered by a 48-year-old man.
New research examined what tools people who have food allergies use to prevent allergic reactions at restaurants.
What happens if you leave your epinephrine auto injector in your car in winter and it freezes? More than likely it will still work, according to new research.
For more than four years, a team of LJI scientists led by Associate Professor Pandurangan Vijayanand, M.D., Ph.D., has been undertaking a massive immunoprofiling effort, detailing how variations in DNA sequence impact gene activity in different types of immune cells.
SBP today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating an inflammation-inhibiting biologic that arose from a research collaboration between Eli Lilly and Company (Lilly) and SBP formed in 2015.
A new study shows that the genotype of a child with severe combined immune deficiency (SCID) affects his survival rate after stem cell transplantation from an unrelated donor.
The National Institutes of Health awarded Tulane University School of Medicine a contract for up to $8.5 million over five years to develop a more effective and longer-lasting vaccine against pertussis, more commonly known as “whooping cough.”
The latest study by researchers at the La Jolla Institute for Immunology (LJI) and their collaborators provide the first in-depth characterization of the body’s cytotoxic T cell response to Zika, which plays an important role in providing protective immunity against Zika.
Using freshly resected lung tissue from 21 patients and two distinct mouse models, tuberculosis researchers at the University of Alabama at Birmingham and the Africa Health Research Institute have identified a protein that plays an essential role in host defense against this deadly disease.
IU scientists have found that drug-delivering nanoparticles attach to their targets differently based upon their position in time. The discovery could improve methods for screening drugs for therapeutic effectiveness.
The MidAtlantic AIDS Education and Training Center (MAAETC) will collaborate with UPMC and local HIV stakeholders to host an all-day educational forum to celebrate the 30th Anniversary of World AIDS Day and the 30th Anniversary of the MAAETC.
Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient. Findings from a new study could lead to big cost savings. In 50 percent of patients, the standard 12-week treatment regimen could be shortened to as little as six weeks without compromising efficacy.
The mechanisms that trigger the elimination of T cells that pose autoimmune dangers work very mechanically via physical forces. Nascent T cells must loosen their grip on human antigens within a reasonable time, in order to advance and defend the body. But if the nascent T cells, thymocytes, grip the human antigens too tightly, the immune cells must die. Here's how the grip of death works.
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors. The paradoxical findings, published today in Nature Medicine, give cancer doctors important new information when choosing drugs and other treatments for cancer patients.
A research team from Massachusetts Eye and Ear describes a newly discovered mechanism in a report published in the Journal of Allergy and Clinical Immunology (JACI). The findings shed new light on our immune systems — and also pave the way for drug delivery techniques to be developed that harness this natural transportation process from one group of cells to another.
SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that more than half of pediatric liver transplant recipients are under-immunized at the time of their transplant and are at increased risk for vaccine-preventable infections.
When melanoma turns metastatic, it spreads to the brain in more than 40% of patients. Published today in the Journal of Clinical Oncology (JCO), a study by Yale Cancer Center researchers show a checkpoint inhibitor immunotherapy drug has meaningful benefit for these patients.
Leading cancer researcher, Alex Huang MD, PhD, has been awarded a three-year, $1.35 million grant from the St. Baldrick’s Foundation and the Osteosarcoma Collaborative to develop new ways to treat osteosarcoma, a rare cancer that begins in the bone.
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.
Scientists led by Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have discovered a gene signature biomarker that may predict which patients will respond – or not – to immune therapy.
This month's Fred Hutch tip sheet includes story ideas about understanding how skin stops tumor growth, advances in studying Kasposi sarcoma, and forecasting the flu. To pursue any of these stories ideas, contact the person listed.
The Endocrine Society is calling for nominations for the 12th annual Award for Excellence in Science and Medical Journalism. The award recognizes outstanding reporting that enhances public understanding of health issues pertaining to the field of endocrinology.
The immune system might play an important role in the development of postpartum depression after a stressful pregnancy, new research suggests.
A new immunotherapy screening prototype developed by University of California, Irvine researchers can quickly create individualized cancer treatments that will allow physicians to effectively target tumors without the side effects of standard cancer drugs.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right